These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. [Parkinsonian disorders: from clinical manifestations to diagnostic classification]. Bourdain F; Tir M; Trocello JM Rev Med Interne; 2013 Sep; 34(9):528-37. PubMed ID: 23142125 [TBL] [Abstract][Full Text] [Related]
63. Neuropathology of movement disorders. Jellinger KA Neurosurg Clin N Am; 1998 Apr; 9(2):237-62. PubMed ID: 9495889 [TBL] [Abstract][Full Text] [Related]
64. Evaluation of the Braak staging scheme for Parkinson's disease: introduction to a panel presentation. Burke RE Mov Disord; 2010; 25 Suppl 1():S76-7. PubMed ID: 20187252 [TBL] [Abstract][Full Text] [Related]
65. Visual hallucinations in the differential diagnosis of parkinsonism. Bertram K; Williams DR J Neurol Neurosurg Psychiatry; 2012 Apr; 83(4):448-52. PubMed ID: 22228724 [TBL] [Abstract][Full Text] [Related]
66. Dystonia in atypical parkinsonian disorders. Marsili L; Bologna M; Kojovic M; Berardelli A; Espay AJ; Colosimo C Parkinsonism Relat Disord; 2019 Sep; 66():25-33. PubMed ID: 31443953 [TBL] [Abstract][Full Text] [Related]
67. Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. Saeed U; Lang AE; Masellis M Front Neurol; 2020; 11():572976. PubMed ID: 33178113 [TBL] [Abstract][Full Text] [Related]
68. Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Arnold SE; Toledo JB; Appleby DH; Xie SX; Wang LS; Baek Y; Wolk DA; Lee EB; Miller BL; Lee VM; Trojanowski JQ J Comp Neurol; 2013 Dec; 521(18):4339-55. PubMed ID: 23881776 [TBL] [Abstract][Full Text] [Related]
70. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Litvan I; Bhatia KP; Burn DJ; Goetz CG; Lang AE; McKeith I; Quinn N; Sethi KD; Shults C; Wenning GK; Mov Disord; 2003 May; 18(5):467-86. PubMed ID: 12722160 [TBL] [Abstract][Full Text] [Related]
71. Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Saeed U; Compagnone J; Aviv RI; Strafella AP; Black SE; Lang AE; Masellis M Transl Neurodegener; 2017; 6():8. PubMed ID: 28360997 [TBL] [Abstract][Full Text] [Related]
72. [Pharmacological Parkinsonism vs. dementia with Lewy bodies]. Peña Llamas E; Fernández García C; Fernández Blázquez MA Neurologia; 2010 Sep; 25(7):459-61. PubMed ID: 20964993 [No Abstract] [Full Text] [Related]
73. The role of molecular imaging in assessing degenerative parkinsonism - an updated review. Nicastro N; Garibotto V; Burkhard PR Swiss Med Wkly; 2018; 148():w14621. PubMed ID: 29698545 [TBL] [Abstract][Full Text] [Related]
74. Multiple sclerosis and Parkinson's disease: the two faces of neurodegeneration. Report of the first Greek case and review of the literature. Bougea A; Kapaki E; Paraskevas GP; Kilidireas K; Andreadou E Neurol Sci; 2015 Dec; 36(12):2281-5. PubMed ID: 26134747 [TBL] [Abstract][Full Text] [Related]
75. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Katzenschlager R; Lees AJ Curr Opin Neurol; 2004 Aug; 17(4):417-23. PubMed ID: 15247536 [TBL] [Abstract][Full Text] [Related]
76. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Hughes AJ; Daniel SE; Ben-Shlomo Y; Lees AJ Brain; 2002 Apr; 125(Pt 4):861-70. PubMed ID: 11912118 [TBL] [Abstract][Full Text] [Related]